[Federal Register Volume 85, Number 79 (Thursday, April 23, 2020)]
[Notices]
[Page 22743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08560]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Thio Compounds 
and Thalidomide Analogues for the Treatment of Neurological Diseases

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute on Aging and the National Cancer 
Institute, institutes of the National Institutes of Health, Department 
of Health and Human Services, are contemplating the grant of an 
Exclusive Patent License to practice the inventions embodied in the 
U.S. and foreign Patents and Patent Applications listed in the 
Supplementary Information section of this notice to AevisBio, Inc. 
located in 814 W Diamond Ave., Suite 203, Gaithersburg, MD 20870.

DATES: Only written comments and/or applications for a license which 
are received by the National Institute on Aging c/o National Cancer 
Institute's Technology Transfer Center on or before May 8, 2020 will be 
considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Merissa Baxter, Ph.D., Technology Transfer 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm. 
1E406 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, 
MD 20850-9702, Telephone: 240-276-7234, Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectually Property

    United States Patent No. 8,927,725, issued January 6, 2015 and 
entitled ``Thio Compounds'' [HHS Reference No. E-045-2012-0-US-01]; 
United States Patent No. 9,084,783, issued July 21, 2015 and entitled 
``Thio Compounds''[HHS Reference No. E-045-2012-0-US-02]; United States 
Patent No. 9,623,020, issued April 18, 2017 and entitled ``Thio 
Compounds'' [HHS Reference No. E-045-2012-0- US-03]; United States 
Patent No. 10,220,028, issued March 5, 2019 and entitled ``Thio 
Compounds'' [HHS Reference No. E-045-2012-0-US-04]; US Provisional 
Patent Application No. 62/235,105, filed on September 30, 2015 and 
entitled ``Thalidomide Analogs and Methods of Use'' [HHS Reference No. 
E-208-2015-0-US-01]; PCT Patent Application No. PCT/US2016/054430, 
filed on September 29, 2016 and entitled, ``Thalidomide Analogs and 
Methods of Use'' [HHS Reference No. E-208-2015-0-PCT-02]; Australian 
Patent Application No. 2016330967, filed on September 29, 2016 and 
entitled ``Thalidomide Analogs and Methods of Use'' [HHS Reference No. 
E-208-2015-0-AU-03]; Canadian Patent Application No. 3000661, filed on 
September 29, 2019 and entitled ``Thalidomide Analogs and Methods of 
Use'' [HHS Reference No. E-208-2015-0-CA-04]; European Patent 
Application No. 16782148.7, filed on September 29, 2019 and entitled 
``Thalidomide Analogs and Methods of Use'' [HHS Reference No. E-208-
2015-0-EP-05]; South Korean Patent Application No. 10-2018-7012347, 
filed on April 13, 2018 and entitled ``Thalidomide Analogs and Methods 
of Use'' [HHS Reference No. E-208-2015-0-KR-06]; and United States 
Patent Application No. 15/764,193, filed on March 28, 2018 and entitled 
``Thalidomide Analogs and Methods of Use'' [HHS Reference No. E-208-
2015-US-07].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be world-wide, and 
the field of use may be limited to the use of Licensed Patent Rights 
for the following: ``The development, production, and commercialization 
of a select subset of thalidomide/lenalidomide/pomalidomide (POMA) 
analogue compounds for the therapeutic treatment of neurological 
disorders prevalent in aging: Specifically, Traumatic Brain Injury 
(TBI), Alzheimer's disease (AD), Parkinson's disease (PD), and Multiple 
Sclerosis (MS).''
    These technologies disclose novel thalidomide, lenalidomide, and 
pomalidomide analogues that can potentially be used for the treatment 
of neurological diseases, autoimmunity, and/or cancer.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Institute on Aging receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: April 13, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2020-08560 Filed 4-22-20; 8:45 am]
 BILLING CODE 4140-01-P